SHI Yixin, WANG Yuekun, XING Hao, CHEN Wenlin, LIU Delin, ZHAO Binghao, YANG Tianrui, NIU Pei, WANG Yu, MA Wenbin. Diagnosis and Treatment Experience of Multidisciplinary Team for Brain Metastasis in Peking Union Medical College Hospital: A Summary of 159 Cases[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 306-314. DOI: 10.12290/xhyxzz.2022-0268
Citation: SHI Yixin, WANG Yuekun, XING Hao, CHEN Wenlin, LIU Delin, ZHAO Binghao, YANG Tianrui, NIU Pei, WANG Yu, MA Wenbin. Diagnosis and Treatment Experience of Multidisciplinary Team for Brain Metastasis in Peking Union Medical College Hospital: A Summary of 159 Cases[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 306-314. DOI: 10.12290/xhyxzz.2022-0268

Diagnosis and Treatment Experience of Multidisciplinary Team for Brain Metastasis in Peking Union Medical College Hospital: A Summary of 159 Cases

Funds: 

National Natural Science Foundation of China 82151302

Beijing Municipal Natural Science Foundation 19JCZDJC64200(Z)

Beijing Municipal Natural Science Foundation 7202150

Tsinghua University-Peking Union Medical College Hospital Initiative Scientific Research Program 2019ZLH101

More Information
  • Corresponding author:

    WANG Yu, E-mail: ywang@pumch.cn

    MA Wenbin, E-mail: mawb2001@hotmail.com

  • Received Date: May 09, 2022
  • Accepted Date: June 05, 2022
  • Available Online: March 15, 2023
  • Issue Publish Date: March 29, 2023
  •   Objective  The prognosis of patients with brain metastases is poor and lacking in unifieddiagnosis and treatment standards. The demand for multidisciplinary team(MDT) diagnosis and treatment mode is extremely high. This study retrospectively summarizes the data of patients treated with MDT for brain metastases in order to provide clinical reference.
      Methods  All patients undergoing MDT treatment for brain metastases at the Neurological Tumor Center of Peking Union Medical College Hospital from January 2019 to December 2021 were retrospectively included. The clinical characteristics, diagnosis and treatment decisions, treatment compliance, clinical prognosis, etc. at the time of enrollment were summarized, and the influencing factors of patients' prognosis were analyzed.
      Results  A total of 159 patients who underwent MDT for brain metastases were included(13 cases with non-cerebral metastases). The most common source of tumor was lung cancer(61.6%), followed by breast cancer(11.3%). The vast majority of patients(87.4%) received only 1 MDT visit. The main characteristics of patients at the time of the initial MDT consultation for brain metastases were primary diagnosis of brain metastases(90.6%), good general condition(Karnofsky functional status score ≥70, 79.2%), age ≤65 years(78.6%), pathological findings of primary site or intracranial metastases(67.9%), tumor origin of lung cancer(61.6%), and single intracranial lesion(54.1%). 76.7%(122/159) of the patients reaching specific treatment recommendations after MDT diagnosis and treatment, 9.4%(15/159) of the patients having changes in diagnosis, and 56.6%(90/159) of the patients exercising full compliance with MDT diagnosis and treatment recommendations at the time of 1-year follow-up. The 6-month survival rate of the 146 patients with brain metastases was 85.6%(125/146) and the 1-year survival rate was 78.8%(115/146). Kaplan-Meier survival curve showed that recursive partition analysis grading and grading prognosis evaluation score had guiding significance for prognosis stratification of patients with brain metastases. Multivariate Cox regression analysis showed that women(HR=0.437, 95% CI: 0.231-0.828) and patients with brain metastases who fully complied with MDT diagnosis and treatment recommendations(HR=0.498, 95% CI: 0.264-0.942) generally had a better prognosis.
      Conclusions  It is necessary to set reasonable conditions for patients with brain metastases to be enrolled in order to improve the diagnosis and treatment efficiency of MDT. Most patients with brain metastases reached specific treatment recommendations after MDT diagnosis and treatment, and the patients had good treatment compliance. The diagnosis and treatment of MDT may help improve the overall survival rate of patients, but the exact benefits need to be evaluated individually.
  • [1]
    Fernando C, Frizelle F, Wakeman C, et al. Colorectal multidisciplinary meeting audit to determine patient benefit[J]. ANZ J Surg, 2017, 87: E173-E177. DOI: 10.1111/ans.13366
    [2]
    Dermine S, Barret M, Prieux C, et al. Impact of a dedicated multidisciplinary meeting on the management of superficial cancers of the digestive tract[J]. Endosc Int Open, 2018, 6: E1470-E1476. DOI: 10.1055/a-0658-1350
    [3]
    El Gammal MM, Lim M, Uppal R, et al. Improved immediate breast reconstruction as a result of oncoplastic multidisciplinary meeting[J]. Breast Cancer, 2017, 9: 293-296.
    [4]
    Rao K, Manya K, Azad A, et al. Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre--impact on clinical decision-making and implications for patient inclusion[J]. BJU Int, 2014, 114: 50-54. DOI: 10.1111/bju.12764
    [5]
    Coory M, Gkolia P, Yang I A, et al. Systematic review of multidisciplinary teams in the management of lung cancer[J]. Lung cancer, 2008, 60: 14-21. DOI: 10.1016/j.lungcan.2008.01.008
    [6]
    Denton E, Conron M, Improving outcomes in lung cancer: the value of the multidisciplinary health care team[J]. J Multidiscip Healthc, 2016, 9: 137-144.
    [7]
    Noyes K, Monson JRT, Rizvi I, et al. Regional Multiteam Systems in Cancer Care Delivery[J]. J Oncol Pract, 2016, 12: 1059-1066. DOI: 10.1200/JOP.2016.013896
    [8]
    Basta YL, Bolle S, Fockens P, et al. The Value of Multidisciplinary Team Meetings for Patients with Gastrointestinal Malignancies: A Systematic Review[J]. Ann Surg Oncol, 2017, 24: 2669-2678. DOI: 10.1245/s10434-017-5833-3
    [9]
    Newman EA, Guest AB, Helvie MA, et al. Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board[J]. Cancer, 2006, 107: 2346-2351. DOI: 10.1002/cncr.22266
    [10]
    Davies AR, Deans DAC, Penman I, et al. The multidisciplinary team meeting improves staging accuracy and treatment selection for gastro-esophageal cancer[J]. Dis Esophagus, 2006, 19: 496-503. DOI: 10.1111/j.1442-2050.2006.00629.x
    [11]
    Turkaj A, Morelli AM, Vavala T, et al. Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer[J]. Front Oncol, 2018, 8: 278. DOI: 10.3389/fonc.2018.00278
    [12]
    Siam L, Bleckmann A, Chaung HN, et al. The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study[J]. Oncotarget, 2015, 6: 29254-29267. DOI: 10.18632/oncotarget.4201
    [13]
    Suh JH, Kotecha R, Chao ST, et al. Current approaches to the management of brain metastases[J]. Nat Rev Clin Oncol, 2020, 17: 279-299. DOI: 10.1038/s41571-019-0320-3
    [14]
    Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors[J]. Onkologie, 2008, 31: 362-365. DOI: 10.1159/000137713
    [15]
    Jenkinson MD, Haylock B, Shenoy A, et al. Management of cerebral metastasis: evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy[J]. Eur J Cancer, 2011, 47: 649-655. DOI: 10.1016/j.ejca.2010.11.033
    [16]
    Loh D, Hogg F, Edwards P, et al. Two-year experience of multi-disciplinary team(MDT) outcomes for brain metastases in a tertiary neuro-oncology centre[J]. Br J Neurosurg, 2018, 32: 53-60. DOI: 10.1080/02688697.2017.1368449
    [17]
    Agboola O, Benoit B, Cross P, et al. Prognostic factors derived from recursive partition analysis(RPA) of Radiation Therapy Oncology Group(RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases[J]. Int J Radiat Oncol Biol Phys, 1998, 42: 155-159.
    [18]
    Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases[J]. J Clin Oncol, 2012, 30: 419-425.
    [19]
    Lamb BW, Sevdalis N, Taylor C, et al. Multidisciplinary team working across different tumour types: analysis of a national survey[J]. Ann Oncol, 2012, 23: 1293-1300. DOI: 10.1093/annonc/mdr453
    [20]
    Lamb BW, Jalil RT, Sevdalis N, et al. Strategies to improve the efficiency and utility of multidisciplinary team meetings in urology cancer care: a survey study[J]. BMC Health Serv Res, 2014, 14: 377. DOI: 10.1186/1472-6963-14-377
    [21]
    Stalfors J, Lundberg C, Westin T. Quality assessment of a multidisciplinary tumour meeting for patients with head and neck cancer[J]. Acta Otolaryngol, 2007, 127: 82-87. DOI: 10.1080/00016480600740589
    [22]
    Bailey M, Qureshi A, Kamaly-Asl I. The role of CT body scans in the investigation of patients with newly diagnosed brain tumours[J]. Br J Neurosurg, 2014, 28: 347-350. DOI: 10.3109/02688697.2013.847169
    [23]
    Palmer JD, Trifiletti DM, Gondi V, et al. Multidisciplinary patient-centered management of brain metastases and future directions[J]. Neurooncol Adv, 2020, 2: vdaa034.
    [24]
    Devitt B, Philip J, McLachlan SA. Team dynamics, decision making, and attitudes toward multidisciplinary cancer meetings: health professionals' perspectives[J]. J Oncol Pract, 2010, 6: e17-e20. DOI: 10.1200/JOP.2010.000023
    [25]
    Team NCA. The Characteristics of an Effective Multidisciplinary team(MDT)[M]. London: National Cancer Action Team, 2010.
    [26]
    Phang I, Leach J, Leggate JRS, et al. Minimally Invasive Resection of Brain Metastases[J]. World Neurosurg, 2019, 130: e362-e367. DOI: 10.1016/j.wneu.2019.06.091
    [27]
    Kotecha RR, Flippot R, Nortman T, et al. Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma[J]. J Natl Compr Canc Netw, 2021, 19: 432-438. DOI: 10.6004/jnccn.2020.7634
    [28]
    刘芃昊, 王月坤, 连欣, 等. 一例肾细胞癌脑转移患者的5次MDT: "量体裁衣"的个体化诊疗模式[J]. 协和医学杂志, 2021, 12: 575-583. DOI: 10.12290/xhyxzz.20200210
  • Related Articles

    [1]MA Xing, LIU Chang. Prognosis and Treatment Strategies of FIGO 2018 Stage ⅢC Cervical Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(6): 1253-1260. DOI: 10.12290/xhyxzz.2024-0097
    [2]ZHOU Gaosheng, WANG Xiaoting, LIU Jingjing, ZHANG Hongmin, ZHANG Qing, LIU Dawei. Relationship between Oxygen Extraction Ratio and Prognosis in Septic Shock Patients During Early Resuscitation[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1217-1223. DOI: 10.12290/xhyxzz.2023-0008
    [3]LIU Huan, HUANG Xiaoling, DAI Mengying, GUO Jiejie, GAO feng. Clinical Characteristics and Inflammatory Markers of Omicron BA.5.2 Variant Infection in Hospitalized Patients and Their Predictive Role in Disease Prognosis[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 1038-1045. DOI: 10.12290/xhyxzz.2023-0055
    [4]ZHANG Ning, ZHU Wen-ling, LIU Xiao-hong, CHEN Wei, KANG Jun-ren, ZHU Ming-lei, TIAN Ran. Impact of Frailty on the Short-term Prognosis of Hospitalized Elderly Patients with Coronary Heart Disease:A Prospective Cohort Study[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 59-66. DOI: 10.12290/xhyxzz.20190150
    [5]Jian-hua DENG, Han-zhong LI. Clinical Diagnosis and Prognosis of Metastatic Pheochromocytoma and Paraganglioma[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 654-659. DOI: 10.3969/j.issn.1674-9081.2019.06.018
    [6]Jia-qi ZHANG, Lei LIU, Gui-ge WANG, Wen-liang BAI, Shan-qing LI. Clinical Pathological Features and Prognosis of Non-small Cell Lung Cancer with Skip N2 Lymph Node Metastasis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 272-277. DOI: 10.3969/j.issn.1674-9081.2019.03.015
    [7]Ran ZHOU, Tong-juan ZOU, Wan-hong YIN, Yao QIN, Yi LI, Jing YANG, Yan KANG. nfluence of Mitral Regurgitation on the Prognosis of Patients with Septic Shock[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(5): 426-430. DOI: 10.3969/j.issn.1674-9081.2018.05.010
    [8]Cheng HUANG, Ye-ye CHEN, Shan-qing LI, Xiao-yun ZHOU, Hong-sheng LIU, Li LI, Ying-zhi QIN, Jia HE, Dong-jie MA. Ectopic Adrenocorticotropic Hormone Syndrome Caused by Thoracic Neuroendocrine Tumors: Surgical Treatment and Prognosis Factors[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 147-153. DOI: 10.3969/j.issn.1674-9081.2017.03.012
    [9]Qing-yuan DENG, Yi-cong YE, Ying ZHONG, Miao-miao SHENG, Feng-ming HUANG, Cheng-yu JIANG, Shu-yang ZHANG. Angiotensin Ⅱ in Predicting the In-hospital Prognosis of Patients Undergoing Elective Percutaneous Coronary Intervention[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(1): 13-17. DOI: 10.3969/j.issn.1674-9081.2016.01.003
    [10]Yu YANG, Quan-zong MAO, Han-zhong LI, Zhi-gang JI, Wei-gang YAN, Shi RONG, Guang-hua LIU, Wei-feng XU, He XIAO, Hui-jun WANG. Clinical Features and Prognosis of Paraneoplastic Syndromes in Renal Malignancies[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(2): 195-199. DOI: 10.3969/j.issn.1674-9081.2012.02.014
  • Cited by

    Periodical cited type(2)

    1. 中国抗癌协会多原发和不明原发肿瘤整合康复专业委员会,陕西省抗癌协会罕见肿瘤专业委员会. 不明原发肿瘤诊疗中国专家共识(2024版). 中华转移性肿瘤杂志. 2025(01): 11-27 .
    2. 吕诗敏,黄海燕,李梅,黄大妹. 优质护理联合多学科协作的安宁疗护方案在恶性肿瘤患者中的应用. 齐鲁护理杂志. 2024(15): 116-118 .

    Other cited types(0)

Catalog

    Article Metrics

    Article views (783) PDF downloads (83) Cited by(2)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close